A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

De-escalating adjuvant therapy following pathologic complete response (pCR) to an abbreviated neoadjuvant regimen in human epidermal growth factor receptor 2-positive (HER2+) breast cancer is the focus of international research efforts. However, the feasibility of this approach and its appeal to pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Waks, Adrienne G., Desai, Neelam V., Li, Tianyu, Poorvu, Philip D., Partridge, Ann H., Sinclair, Natalie, Spring, Laura M., Faggen, Meredith, Constantine, Michael, Metzger, Otto, Alberti, Jillian, Deane, Julia, Rosenberg, Shoshana M., Frank, Elizabeth, Tolaney, Sara M., Krop, Ian E., Tung, Nadine M., Tayob, Nabihah, King, Tari A., Mittendorf, Elizabeth A., Winer, Eric P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091255/
https://www.ncbi.nlm.nih.gov/pubmed/35538105
http://dx.doi.org/10.1038/s41523-022-00429-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091255/
https://www.ncbi.nlm.nih.gov/pubmed/35538105
http://dx.doi.org/10.1038/s41523-022-00429-7

Ejemplares similares